With a more favourable environment, CHINA RES.SANJIU MED.& PHARM.'A' improves to Positive
CHINA RES.SANJIU MED.& PHARM.'A' (CN), a company active in the Pharmaceuticals industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 3 out of 4 stars, as well as its unchanged, defensive market behaviour. The title leverages a more favourable environment and raises its general evaluation to Positive. As of the analysis date March 1, 2022, the closing price was CNY 34.80 and its potential was estimated at CNY 40.52.Sanjiu Medical & Pharmaceutical is engaged in the research, development, production and sale of medicine; development and transfer of related technologies; import of research-needed machineries and equipments and raw materials; and export of Co.'s self-produced products. Through its subsidiaries, Co. is also engaged in the printing and packaging; brain diseases treatment; development of Chinese medicine and organic raw materials; development of computer software, hardware and network; property management; and provision of warehousing, transportation and logistics services.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.